IMCR · Healthcare
Immunocore Hldgs Plc
20/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
27
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$1.8B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About IMMUNOCORE HLDGS PLC
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line…
Who's behind the signal
Every informed buyer we can see on IMCR, across all three feeds.
Hedge funds · 5
Point72 (Steve Cohen)
Increased +119%
Millennium Management (Englander)
Increased +36%
D.E. Shaw & Co
Increased +82%
Bridgewater Associates (Dalio)
Increased +90%
Citadel Advisors
Unchanged
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
IMMUNOCORE HLDGS PLC isn't in the top-10 model right now, but 5 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
5
Investors
0
New positions
4
Increasing
0
Decreasing
1
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.1×
% of portfolio
0.1%
Position change
+119%
0.1% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+36%
0.0% of Millennium Management's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+82%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.3×
% of portfolio
0.0%
Position change
+90%
0.0% of Bridgewater Associates's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
—
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to IMMUNOCORE HLDGS PLC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell IMMUNOCORE HLDGS PLC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订